ENCORE Study for NTM
Trial Objectives
Mycobacterium avium complex (MAC) is the most common cause of nontuberculous mycobacteria (NTM)-associated lung disease in the U.S. It can result in a serious infection and damage to the lungs, especially affecting people with conditions such as lung diseases, autoimmune disorders or medical treatments that compromise the immune system.
In the ENCORE study, researchers are evaluating the effectiveness and safety profile of a study medication on people who have been diagnosed with Nontuberculous Mycobacterial (NTM) lung infection caused by Mycobacterium avium complex (MAC).
By participating in this study, you contribute to the understanding of MAC lung infection, and the information gathered (including information obtained from the sputum, blood sampling and the other tests you complete) may help other patients with MAC lung infections in the future.
Who Can Participate
Adults ages 18 and older with a diagnosis of lung infection caused by Mycobacterium avium complex within the last six months.
Age: 18+ Gender: Any
Estimated Time Commitment
16 study visits over approximately 70 weeks. Five of the visits can be done over the phone instead of in person.
Payment & Reimbursement
Payment: Provided
Travel Reimbursement: Available
Trial Contact
For more information, contact:
Cynthia Wainscoat
303.398.1259
Trial Location
National Jewish Main Campus, Denver, CO
Trial Sponsors
Insmed
Principal Investigators
Charles L. Daley, MD
Co-Investigators
David E. Griffith, MD